Figure 5. Assessment of the growth and invasive advantages provided by senescent fibroblasts to LCC cells in vivo.

A. Outline of the experimental design used to assess tumor growth and lung cancer cell dissemination of H460R LCC cells subcutaneously co-injected alone, with cancer-naive fibroblasts, or with H460-educated senescent CCD-19Lu fibroblasts into immunedeficient mice. B. Percentage of tumor-free flanks monitored over 40 days, i.e. tumors lower than 200 mm³. C. Tumor volume monitored over 40 days (n = 8 tumors per condition). Data are mean ± SE. (D,E) Percentage of lung disseminated tumor cells at D. 30 and E. 50 days after injection. All pair-wise comparisons were performed with respect to H460R injected alone. Statistical significance in (B) was assessed by log-rank test.